Search bioRxiv⌕ Search

Biology subjects

Barman, N.

Publications and source records attributed to Barman, N..

2 recordsLinked to original sources

IL6 mediated cFLIP downregulation increases the migratory and invasive potential of triple negative breast cancer cell line

c-FLIP (cellular FLICE-Like Inhibitor of Apoptotic protein) which belongs to the negative regulators of the death receptor pathway, control apoptosis in a number of cancers. literatures suggest that its overexpression facilitate cancer progression and also helps in the drug resistance. However, there is a very few data available to show how it control metastasis. Moreover, how cFLIP is regulated during the progression of cancer into advanced stage and its mechanism of action on tumor cell migration and invasion is yet to be known. Our TCGA data analysis has shown that cFLIP is downregulated in many cancers, including breast cancer, especially at the later stages. when, we analysed and compared early-stage breast carcinoma cell line MCF7 (luminal) and advanced stage triple negative cell line MDAMB-231, which is highly metastatic, we found a negative correlation between cFLIP expression and metastasis. Our results indicated that Il6, one of the most prominent cytokines inside tumor microenvironment, activated p38 and the later helped in cFLIP downregulation in MDA-MB-231 cell line. Moreover, we have found that cFLIP negatively regulated autophagy and this autophagy downregulation resulted in decrease in metastasis. Thus, we have shown, for the first time, a complete interconnecting pathway in which IL6 mediated p38 activation directly influences metastasis by regulating autophagy via cFLIP downregulation.

cancer biology↗

3-epicaryoptin induces G2/M phase cell cycle arrest and apoptosis in human breast cancer cells by disrupting the microtubule network, an in vitro and in silico investigation

Breast cancer (BC) is a prevalent form of cancer observed in women across the globe, constituting over a quarter of all female BC cases. The treatment of BC continues to require significant efficacy, aiming to achieve high success rates while minimizing adverse effects on the body as a whole. In the current study, 3-epicaryoptin was tested for the molecular mechanism of its anti-cancer activity in the human breast cancer cell line, MCF-7. We investigated cell viability by MTT assay, cell cycle kinetics and apoptosis, immunofluorescence straining, molecular modelling, and ADMET profiling. MTT assay results showed that 3-epicaryoptin was found cytotoxic against MCF-7 cells with an IC50 value of 344.64 {micro}g mL-1 for 48 h. Flow cytometric analysis exhibited that 3-epicaryoptin halted the MCF-7 cells in the G2/M phase and subsequently induced apoptosis in a time-dependent manner. Our immunofluorescence studies indicated that 3-epicaryoptin inhibited microtubule polymerization in MCF-7 cells. Furthermore, molecular docking followed by molecular dynamics (MD) simulation studies demonstrated the ability of 3-epicaryoptin to interact with the tubulin protein at the colchicine binding pockets. Overall, our results suggest that 3-epicaryoptin can inhibit the proliferation of human breast cancer cells by depolymerizing of cellular microtubule networks, which causes cell cycle arrest and promotes apoptotic cell death. Therefore, it has been indicated that the natural product 3-epicaryoptin exhibited considerable promise as a potent therapeutic agent capable of inducing apoptosis in breast cancer cells.

cancer biology↗